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Abstract
Background: The role of epicardial substrate ablation of ventricular tachycardia (VT) as a first-line approach in
patients with ischemic heart disease is not clearly defined. Epicardial ablation as a first-line option is standard for
patients with nonischemic dilated cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy. Several
nonrandomized studies, including studies on patients with ischemic heart disease, have shown that epicardial VT
ablation improves outcome but this approach was often used after a failed endocardial approach. The aim of this
study is to determine whether a combined endo-epicardial scar homogenization as a first-line approach will
improve the outcome of VT ablation.
Methods/Design: The EPILOGUE study is a multicenter, two-armed, nonblinded, randomized controlled trial.
Patients with ischemic heart disease who are referred for VT ablation will be randomly assigned to combined
endo-epicardial scar homogenization or endocardial scar homogenization only (control group). The primary
outcome is recurrence of sustained VT during a 2-year follow-up. Secondary outcomes include procedural
success and safety.
Discussion: This study is the first randomized trial that evaluates the role of a combined endo-epicardial scar
homogenization versus endocardial scar homogenization for the treatment of ischemic scar-related VT.
Trial registration: NL4816807814v02
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Background
Ventricular tachycardia (VT) is an important clinical
sequela after a myocardial infarction and may be asso-
ciated with sudden cardiac death [1]. The introduction
of the implantable cardioverter defibrillator has provided
an important tool in the prevention of sudden cardiac
death. However, a significant proportion of patients
experience multiple appropriate implantable cardioverter
defibrillator shocks due to sustained VT. Catheter abla-
tion of VT is useful to reduce the burden of VT. The
threshold for VT ablation has lowered in recent years,
mainly as a result of technological advancements and in-
creased experience [2–4]. The endocardial approach has
been the preferred first-line approach for VT ablation in
patients with ischemic heart disease.
Recent studies suggest that 12–17 % of all VTs in a
mixed population of ischemic and nonischemic cardio-
myopathies have an epicardial origin [5, 6]. Epicardial
VTs have been observed in 10 % of post-infarction VTs [7].
These numbers may be underestimated, considering the
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moderate outcomes of endocardial VT ablations [8, 9]. In
experienced centers, epicardial VT ablation has an accept-
able risk-to-benefit ratio [6, 10]. Current recommendations
for scar-related VT suggest that patients with ischemic
heart disease can benefit from an epicardial approach if
an endocardial ablation fails [11].
The aim of this randomized trial is to determine whether
combined endo-epicardial scar homogenization as a first-
line approach will improve the outcome of VT ablation in
comparison with endocardial scar homogenization only.
Methods/design
Study design
The EPILOGUE study is a multicenter, two-armed, non-
blinded, randomized controlled trial. Patients will be
randomized to endocardial scar homogenization or endo-
epicardial scar homogenization (Fig. 1). The study period
is 2 years after the index procedure. All participating
centers are tertiary referral centers for VT ablation with
experience in epicardial ablation.
Study population
All patients with a history of ischemic heart disease
who are referred for VT ablation will be considered for
inclusion. Patients can be included if they meet all of
the following inclusion criteria:
 Age ≥18 years;
 History of ischemic heart disease;
Fig. 1 EPILOGUE study flow chart. *Normal recordings are defined as not more than three sharp and discrete deflections from baseline,
amplitude >1.5 mV, duration >70 ms or amplitude-to-duration ratio >0.046. FU, follow-up; VT, ventricular tachycardia
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 Presence of or planned-for implantable cardioverter
defibrillator soon after VT ablation.
Patients will be excluded if they meet any of the fol-
lowing criteria:
 Presence of unstable angina;
 Acute myocardial infarction <30 days (or in case of
incessant VT, <14 days);
 Absence of visualization of coronary anatomy
(coronary angiogram or computed tomography);
 Presence of significant coronary stenosis clinically
relevant for intervention;
 Presence of mobile left ventricular thrombus;
 Presence of aortic or mitral mechanical valve
prosthesis;
 Previous pericarditis;
 Previous coronary artery bypass graft;
 Other factors that could potentially lead to pericardial
adhesion (e.g., thoracic radiation therapy);
 Contra-indication for general anesthesia.
Ethics
The study protocol was approved in February 2015 by
the Medical Ethical Committee (2014–248) Erasmus
Medical Center, Rotterdam, The Netherlands. Informed
consent will be obtained from each participant.
Primary and secondary outcomes
The primary outcome of this study is recurrence of sus-
tained VT (defined as appropriate implantable cardioverter
defibrillator therapy or VT >30 s duration) within 2 years.
We will use a blanking period of 1 week after the ablation
procedure. The secondary outcome parameters will be
acute procedure success and procedure-related major
complications. Procedural success will be defined as
complete success if there is noninducibility of any sus-
tained monomorphic VT. Partial success will be defined
as noninducible clinical VT but inducible polymorphic
VT, or VT with a cycle length <200 ms. Procedural failure
will be defined as a spontaneous occurrence of VT or
inducible clinical monomorphic VT.
Furthermore, the following data will also be determined:
procedure time, fluoroscopy time, radiofrequency ablation
time, time to recurrence of the ventricular arrhythmia,
number of appropriate implantable cardioverter defibrilla-
tor therapies on follow-up, number of VT-related hospitali-
zations, freedom of antiarrhythmic drugs on follow-up,
repeated (epicardial) ablation procedures, evidence of an in-
cessant VT or VT storm during follow-up, and mortality.
Study groups
This study has two study arms, the endocardial approach
only and the combined endocardial and epicardial approach
(combined approach). Crossover is not allowed during the
first procedure. When a patient is randomized to the com-
bined approach and the epicardial access is unsuccessful,
this is considered a screening failure.
Randomization
Patients are randomized to either the endocardial approach
or the combined endocardial and epicardial approach.
Randomization is performed using a computer-generated
program (ALEA). The person carrying out randomization
will not be the treating physician or involved in the selec-
tion procedure. The patient and the electrophysiologist
who will be performing the procedure will not be blinded
for the method of approach.
Electrophysiology procedure and catheter ablation
Pre-procedural preparation
In general, anticoagulation therapy will be discontinued
before the procedure (unless the operator decides other-
wise). When performing the pericardial puncture, the
international normalized ratio should be <2.0. Trans-
thoracic echocardiography will be used to exclude a
thrombus in the left ventricle. If the transthoracic
echocardiography is inconclusive, contrast transtho-
racic or transesophageal echocardiography will be used.
Antiarrhythmic medications will be stopped 5 days be-
fore the procedure. In case of an emergency VT abla-
tion, the operator can choose to do the ablation while
continuing antiarrhythmic drugs. Patients who undergo
an epicardial ablation will receive general anesthesia;
otherwise conscious sedation and local anesthesia will
be used. The epicardial ablation is performed with a
surgical team as backup.
Pericardial access
In patients undergoing epicardial ablation, before abla-
tion and systemic heparinization, subxiphoid pericardial
access will be obtained by fluoroscopic guidance (lateral
plane). Using a Tuohy needle, small amounts of contrast
are injected while carrying out the puncture. Guided by
fluoroscopy, a guide wire is inserted into the pericardial
space and an Arrow sheath is placed. An appropriate
sized guiding catheter is inserted to keep the sheath
open. During ablation, we will use an irrigated tip cath-
eter. The baseline flow should be reduced to 1 ml/min.
Fluid will be drawn from the pericardial space frequently
during the ablation.
At the discretion of the operator, epicardial phrenic
nerve capture will be performed if the origin of the VT
is located in the area of the phrenic nerve. When cap-
ture is performed, a balloon is inserted and inflated to
avoid phrenic nerve damage during ablation.
At the end of the procedure, a pericardial drain is
inserted for 24–48 h. The operator will administer an
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intrapericardial steroid injection. Colchicine should be
prescribed for up to 1 month, commencing on the first
day after the procedure. The first day post procedure
Colchicine is dosed 1 mg twice daily followed by a main-
tenance dose of Colchicine 0.5 mg twice daily.
Mapping
Endocardial mapping will be performed in all patients.
A multipolar diagnostic catheter will be placed in the
coronary sinus. A quadripolar diagnostic catheter will
be introduced via the femoral vein to the right ventricular
apex. Left ventricle mapping will be performed via the
retrograde aortic or transseptal approach. The procedure
will be performed under intravenous anticoagulation with
heparin, with a target activated clotting time >250 s.
Electroanatomical maps will be obtained using CARTO
3 (Biosense Webster, Diamond Bar, CA, USA) or EnSite
NavX (St. Jude Medical, St. Paul, MN, USA). This includes
activation (if applicable) and voltage maps. The bipolar
voltage thresholds used to consider dense scar and border
zone will be 0.5 and 1.5 mV, respectively. We will aim to
acquire a very dense map, especially around scar areas.
Areas of fractionated or late potentials will be annotated.
Programmed ventricular stimulation will be performed,
and will involve three extra stimuli from two different
right ventricular sites, high-rate pacing, and intravenous
isoproterenol (at the discretion of the operator). In
hemodynamically unstable VTs mechanical circulation
support (Impella, intra-aortic balloon pump) can be
considered.
Ablation protocol (both groups)
If a hemodynamically tolerated VT is induced during
the electrophysiological study, a standard activation or
entrainment mapping is carried out. The ablation will
continue until the VT is no longer inducible. Addition-
ally, endocardial scar homogenization will be performed.
Based on the substrate map, ablation will be empirically
extended throughout the entire scar endocardially. Also
delayed and fractionated electrograms will be targeted
for ablation. If clinical VT is still inducible in the endo-
cardial ablation-only group, an epicardial VT ablation
will be performed in a ‘redo’ procedure. Epicardial map-
ping and ablation will be performed as described in the
combined approach.
Combined endocardial and epicardial group ablation
After obtaining pericardial access, a substrate map is
constructed to identify abnormal electrograms. Activa-
tion mapping during VT – if possible – is done to prove
epicardial involvement. Normal electrogram recordings
show not more than three sharp and discrete deflections
from baseline, amplitude >1.5 mV, duration <70 ms or
amplitude-to-duration ratio >0.046 [9]. Before epicardial
ablation, a coronary angiogram will be performed to
avoid coronary artery damage. In addition to targeting
abnormal potentials, epicardial homogenization will be
performed. Ablation is continued until all abnormal po-
tentials are gone.
Clinical outcome and follow-up
Patients will be seen periodically up to 2 years (at 1, 3, 9,
12, and 24 months) after the index procedure. All im-
plantable cardioverter defibrillator therapies and clinical
events are reported.
The implantable cardioverter defibrillator will be pro-
grammed to detect VTs slower than the clinical VTs.
Recommended implantable cardioverter defibrillator
programming consists of a ventricular fibrillation zone
with a cut-off rate of 220 beats per minute and a thera-
peutic VT zone with a cut-off cycle length of 60 ms
below the slowest documented VT. To register VTs
with rates below the detection limit, a monitor zone
will be programmed with a cut-off rate of 120 beats per
min. Detection duration will be 24/32 beats or 5 s in
the ventricular fibrillation zone and 26 beats or 10 s in
the therapeutic VT zone.
The analysis of recurrence of VT depends on the clear
differentiation of VT from supraventricular tachycardia
events. For reliable adjudication of arrhythmic events,
implantable cardioverter defibrillator episodes with avail-
able electrograms are mandatory. In the case of single-
chamber devices, the recommended setting is storage of
both near-field and far-field (shock) electrogram sources.
In addition, electrogram storage must be available before
arrhythmia onset.
Adverse events
In compliance with medical ethics committee regulations,
it is compulsory to register all serious adverse events.
Death, acute myocardial infarction, coronary artery dam-
age, type III and V major bleeding, abdominal bleeding,
tamponade of more than 80 cm3, late tamponade, and an
ischemic cerebral event are considered major adverse
events. Dry right ventricle puncture, drainable hemoperi-
cardium, postprocedural precordial pain, phrenic nerve in-
jury and type II minor bleeding [12] are considered minor
adverse events.
Safety monitoring
Two committees and one monitor will be appointed to
monitor patient safety. A data safety monitoring board
will review study progress and has the authority to end
the study if significant benefits or adverse effects in
either study arm are suspected. The board members are
three experienced electrophysiologists and a statistician.
The clinical events committee will study all serious
adverse events for a causal relationship between events
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and the EPILOGUE study. A monitor will evaluate
protocol compliance by taking random samples in all
participating centers.
Statistical analysis
Continuous variables between groups will be compared
using Student’s t test or the Mann–Whitney test for
continuous variables, where appropriate. Categorical
variables between groups will be compared with the
chi-square test or Fisher’s exact test, where appropriate.
The primary outcome parameter will be analyzed using
Kaplan–Meier survival curves and tested with a log-rank
test. A two-sided P value of 0.05 will be considered statis-
tically significant for all analyses. Statistical analysis will be
performed using SPSS version 20.
Sample size calculation
Sample size was calculated based on the following as-
sumptions: a 29 % difference in primary outcome event
rate (recurrence of VT) between the endocardial and epi-
cardial group (15 %) and the control group (44 %) after a
follow-up time of 2 years [9]. We calculate that a sample
size of 86 patients is required to achieve an 80 % power
to detect a significant difference with a (two-tailed) alpha
error of 5 %. Allowing for a dropout rate of 10 %, we
calculated that we would require 100 subjects.
Discussion
Mechanism of scar-related ventricular tachycardia
Sustained VT in the presence of coronary artery disease
is most often the result of prior myocardial infarction
[13]. Scar areas form the substrate for macro-reentry
which is the most frequent mechanism underlying VT.
Targets for ablation are the area of low bipolar voltage
that corresponds to the subendocardial projection of the
scar, and potential targets within the scar that represent
critical diastolic isthmuses during VT.
Role of epicardial ablation
In 73 % of unsuccessful endocardial ablations, evidence
of an epicardial substrate of VT was found [14]. To
reach procedural success in VT ablation, Cesario et al.
[15] found that 40 % of the patients were in need of an
epicardial ablation. A recent retrospective observational
study from Tung et al. [16] compared the outcomes of
patients who underwent epicardial ablation with the out-
comes of patients who did not. The pericardial space
could not be accessed in 7 % by the percutaneous tech-
nique. The study demonstrated that at 12 months those
with an ischemic substrate for VT who underwent a
combined endocardial and epicardial ablation had im-
proved freedom from VT compared with those who
underwent endocardial-only ablation (85 % versus 56 %;
P = 0.03). In a multicenter study by Della Bella et al. [5],
67 % of a subgroup of patients with ischemic VT eti-
ology were in need of a stepwise approach. It could be
speculated that an endocardial and epicardial approach
as a first-choice ablation strategy in this subgroup might
have avoided a substantial number of repeat procedures
and improved outcome.
Epicardial ablation in ischemic cardiomyopathy
Multiple studies on epicardial VT ablation in scar-related
VT have been published [5, 9, 15, 17, 18]; however, few
have compared endocardial ablation with a combined
endocardial and epicardial ablation.
In 33 post-infarct patients [17], epicardial mapping was
performed when endocardial ablation failed. These 33 pa-
tients were retrospectively compared with patients who
had had an endocardial ablation only. There was found to
be no difference in outcome. However, only 6 % of the pa-
tients had had an epicardial ablation.
A recent study from Di Biase et al. [9] compared limited
endocardial substrate ablation with combined endocardial
and epicardial scar homogenization in patients with an
electrical storm and ischemic cardiomyopathy. There was
a lower VT recurrence rate in those who underwent endo-
cardial and epicardial scar homogenization during a mean
follow-up of 25 months (19 % versus 47 %; P = 0.006). A
limitation of this study is that because these researchers
used a historical control group, the technique of ablation
(limited substrate ablation versus scar homogenization)
differed between groups.
Safety of epicardial ablation
The reported complication rates associated with epicardial
ablation range from 0.6 to 4.1 % [5, 6]. Procedure-related
death in most studies was 0 % [5, 6, 16]. However, a study
from Hamburg reported two procedure-related deaths in
59 patients undergoing epicardial VT ablations [14]. Thus,
life-threatening complications might occur. Other reported
major complications were [5, 6, 9, 16]:
 Hepatic bleeding;
 Pericardial bleeding requiring a drain;
 Phrenic nerve palsy;
 Pleuro-pericardial fistula;
 Coronary artery damage;
 Cardiac tamponade;
 Pericardial inflammatory reaction.
To prevent pericardial inflammation and subsequently
adhesions, the use of colchicine after epicardial ablation
is mandatory in our study [19].
Study design
The study of Di Biase et al. [9] was a retrospective compari-
son of two techniques. Although there was a well-written
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prospective protocol, the two well-known techniques are
difficult to compare. In the absence of a large scar or in the
presence of dense scars, patients did not undergo epicardial
ablation. Only 14 out of 43 patients (33 %) in the endocar-
dial and epicardial scar homogenization group underwent
epicardial VT ablation. In the current study both groups
will undergo scar homogenization. Patients randomized to
the combined approach will undergo epicardial ablation
unless there is a complete absence of abnormal recordings.
The EPILOGUE study is the first randomized controlled
study to compare a combined approach with a stepwise
approach for VT ablation in patients with ischemic
cardiomyopathy.
Limitations
This study is an open study that may subsequently lead
to bias. However, the primary endpoint is recurrence of
VT, an objective endpoint. Patients who have had a coron-
ary artery bypass graft will be excluded from this study,
thereby excluding a relevant part of the scar-related VT
population. Open heart surgery is a known risk factor for
adhesions and has shown to limit epicardial VT ablation
[16]. When considering that VT ablation is not yet general
practice, the inclusion rate may be low. This approach
may change in following years as a consequence of im-
proved understanding of the underlying pathophysiology
or mechanism of VT.
Trial status
Inclusion of eligible candidates in the EPILOGUE study
has not yet started; enrolment is expected to start in
May 2015.
Abbreviation
VT: ventricular tachycardia.
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